Biomarkers, precision medicine, early detection to revolutionize CRC care in India: Dr. Sumant Gupta: Shardul Nautiyal, Mumbai Saturday, April 12, 2025, 08:00 Hrs [IST] Molecular ...

Opdivo是一种PD-1免疫检查点抑制剂，旨在帮助恢复抗肿瘤免疫反应，利用人体自身的免疫系统来对抗癌症。Yervoy则靶向抑制CTLA-4。CTLA-4抗体通过增强T细胞活性来提高肿瘤杀伤能力。该产品已于2011年获得美国FDA批准治疗晚期黑色素瘤，是全球首个获批上市的CTLA-4抗体药物。

2025 年 4 月 8 日，美国食品药品监督管理局（FDA）批准百时美施贵宝公司的双免疗法——纳武利尤单抗（欧狄沃，俗称O药）+伊匹木单抗（逸沃，俗称Y药）用于治疗患有不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复缺陷（dMMR）结直肠癌（CRC）成人和 ≥12 岁儿童患者。

为探究溶组织内阿米巴（ Entamoeba histolytica ）在微卫星不稳定（MSI）中的作用及 miRNA-643 作为生物标志物的潜力，研究人员对 150 例结直肠腺癌活检样本进行研究。结果发现部分样本 MSI 与 Eh-lectin 共现，且 miRNA-643 表达增加。该研究为结直肠癌诊疗提供新思路。

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

Motorola Solutions today announced the APX® N70 XE smart radio that combines mission-critical voice communications with smart data applications that provide essential location and incident information ...

子宫内膜癌（endometrialcarcinoma, EC）是全球第6大最常见癌症，同时也是美国第二大常见癌症，预计到2023年，美国将有66 200例新发病例。在中国，2022年约有新发病例77 700例，死亡病例13 ...

Bristol Myers Squibb’s Opdivo plus Yervoy gets US FDA nod to treat adult and pediatric patients with mismatch repair deficient colorectal cancer: Princeton, N.J. Thursday, April ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.